Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INTUITIVE SURGICAL, INC.

(ISRG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/23/2021 07/26/2021 07/27/2021 07/28/2021 07/29/2021 Date
976.46(c) 966.1(c) 975.08(c) 972.5(c) 981.49(c) Last
439 279 534 817 357 657 323 818 316 411 Volume
+0.26% -1.06% +0.93% -0.26% +0.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 5 643 M - -
Net income 2021 1 657 M - -
Net cash position 2021 3 029 M - -
P/E ratio 2021 79,0x
Yield 2021 -
Sales 2022 6 398 M - -
Net income 2022 1 648 M - -
Net cash position 2022 4 508 M - -
P/E ratio 2022 74,0x
Yield 2022 -
Capitalization 117 B 117 B -
EV / Sales 2021 20,1x
EV / Sales 2022 17,5x
Nbr of Employees 8 081
Free-Float 99,0%
More Financials
Company
Intuitive Surgical, Inc. develops, manufactures and markets the da Vinci surgical system and Ion endoluminal system. The Company's da Vinci products are offered in categories, including da Vinci Surgical Systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems (Firefly) and da Vinci Endoscopes. It also provides a... 
More about the company
Ratings of Intuitive Surgical, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about INTUITIVE SURGICAL, INC.
07/22INTUITIVE SURGICAL : Deutsche Bank Adjusts Price Target for Intuitive Surgical t..
MT
07/21INTUITIVE SURGICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
07/21Tranche Update on Intuitive Surgical, Inc.'s Equity Buyback Plan announced on..
CI
07/21Today on Wall Street: Earnings season picks up pace
07/21INTUITIVE SURGICAL : Evercore ISI Adjusts Intuitive Surgical's Price Target to $..
MT
07/21INTUITIVE SURGICAL : JPMorgan Adjusts Price Target for Intuitive Surgical to $1,..
MT
07/21INTUITIVE SURGICAL : Baird Adjusts Price Target on Intuitive Surgical to $1,050 ..
MT
07/21INTUITIVE SURGICAL : Wells Fargo Adjusts Intuitive Surgical's Price Target to $1..
MT
07/21INTUITIVE SURGICAL : Morgan Stanley Adjusts Price Target on Intuitive Surgical t..
MT
07/21INTUITIVE SURGICAL : Piper Sandler Adjusts Price Target on Intuitive Surgical to..
MT
07/21INTUITIVE SURGICAL : Citigroup Adjusts Intuitive Surgical's Price Target to $1,1..
MT
07/21ANALYST RECOMMENDATIONS : Avast, Asos, Compass, Halliburton, Intertek...
07/21INTUITIVE SURGICAL : SVB Leerink Adjusts Price Target on Intuitive Surgical to $..
MT
07/20Intuitive Surgical 2Q Net Jumps on Growth in Da Vinci Procedures
DJ
07/20INTUITIVE SURGICAL : ANNOUNCES SECOND QUARTER EARNINGS (Form 8-K)
PU
More news
News in other languages on INTUITIVE SURGICAL, INC.
07/21MÄRKTE USA/Wall Street bleibt auf Erholungskurs
07/20EN DIRECTO DESDE LOS MERCADOS : Facebook, LVMH, Microsoft, Apple, Tarkett, IBM, ..
07/20El coronavirus vuelve a infectar los índices bursátiles
07/20STOCK MARKET PARIS : Le coronavirus contamine à nouveau les indices
07/20EN DIRECT DES MARCHES : LVMH, Alstom, Rémy Cointreau, Tarkett, IBM, UBS, Volvo, ..
More news
Analyst Recommendations on INTUITIVE SURGICAL, INC.
More recommendations
Chart INTUITIVE SURGICAL, INC.
Duration : Period :
Intuitive Surgical, Inc. Technical Analysis Chart | ISRG | US46120E6023 | MarketScreener
Technical analysis trends INTUITIVE SURGICAL, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 981,49 $
Average target price 983,56 $
Spread / Average Target 0,21%
EPS Revisions
Managers and Directors
Gary S. Guthart President, Chief Executive Officer & Director
Marshall L. Mohr Chief Financial Officer & Executive Vice President
Calvin Darling Senior Director-Finance & Investor Relations
Craig H. Barratt Chairman
Myriam J. Curet Chief Medical Officer & Executive Vice President
Sector and Competitors